Paper Details
- Home
- Paper Details
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Author: BassD, DoriaA, FoxN L, GordonD, GroarkJ, HammerA, KleoudisC, RothD, ScheinbergM, SchwartingA, StohlW
Original Abstract of the Article :
Objective To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. Methods This was a 24-week, open-label extension following a 52-week, double-blind, placebo-controlled trial of belimumab SC. Patients who com...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066857/
データ提供:米国国立医学図書館(NLM)
A Long-Term Look at Belimumab for Lupus
The world of autoimmune diseases, like systemic lupus erythematosus (SLE), can feel like a vast desert, full of challenges for patients and researchers. This study delves into the long-term safety and effectiveness of belimumab, a medication used to treat SLE. This is a kind of oasis in the research landscape, offering a potential solution for a complex and often debilitating condition. The researchers used an open-label extension study, which means all participants knew they were receiving belimumab, allowing for a close look at its effects over a longer period. The primary goal was to see if belimumab continued to be safe and helpful beyond the initial year of treatment.
Belimumab Holds Up Over Time
The results were promising. Belimumab's safety profile remained consistent with previous findings, a reassuring sign for patients who might be considering this treatment. Furthermore, the medication continued to improve SLE symptoms even after a year of use. In fact, the study found that belimumab was particularly beneficial for those who hadn't shown significant improvement after the initial placebo-controlled phase.
Navigating the Desert of Lupus Treatment
These findings are a beacon of hope for individuals grappling with SLE. While belimumab may not be a cure, it can provide a lifeline in the challenging desert of this autoimmune condition. The long-term safety and effectiveness of belimumab suggest that it could become a valuable part of a multi-faceted approach to managing SLE, allowing patients to live a more fulfilling life.
Dr. Camel's Conclusion
This study is a valuable addition to the field of SLE research. By exploring the long-term effects of belimumab, researchers have shed light on the potential of this medication to improve the lives of patients. While the desert of SLE may be vast, belimumab offers a ray of hope, a promising oasis for those seeking relief from its harsh conditions.
Date :
- Date Completed 2018-12-11
- Date Revised 2022-04-08
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.